Posts Tagged ‘pharmaceutical recruitment’

Pfizer Retains Pharma Jobs in Kent

Tuesday, July 5th, 2011

Drugs giant Pfizer has announced it will retain 350 jobs in a pharmaceutical sciences operation, whilst still going forward with the planned reduction of the research and development facility in Sandwich, Kent, the Independent reports.

Pfizer hopes the retention of a presence on the site will encourage investors and support the current development of products, despite the loss of around 2,000 jobs at the site. The company will also be working in tandem with Kent County Council in order to encourage other businesses and investors to settle on the site.

Pfizer has a long relationship with Sandwich stretching over 50 years, with a variety of medical discoveries being made there, including that of Viagra.

Looking for a job in science? Start looking here

Pfizer to Cut 2,400 Pharmaceutical Jobs

Tuesday, February 1st, 2011

As reported by Sky News, the US Pharmaceutical company, Pfizer has this afternoon announced their plans to close their site in Sandwich, Kent, cutting up to 2,400 pharmaceutical jobs.

The research and development centre will be closing down over the next two years. Speaking of the closure, Dr Ruth McKernan, the company’s head stated, “It is with a deep sense of sadness that we announce our proposal to exit our site in Sandwich, Kent.

“It has played an important role in the discovery and development of medicines and has brought many life-saving treatments to patients.”

The closure is part of a plan by the pharma company to partake in a global restructuring programme in order to, “to create a more focused and sustainable R&D engine for innovation”.

Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.

Roche to Cut 4800 Pharma Jobs

Wednesday, November 17th, 2010

joblossesIt has been announced that the Swiss pharmaceutical company Roche, plans to cut 6 per cent of their global workforce over the next 2 years.  The pharmaceutical job cuts come in an effort by the pharma company to make annual costs savings totalling 2.4 billion Swiss Francs.

Speaking of the cost cutting initiative, CEO Severin Schwan stated it was designed to “to reinforce Roche’s long-term innovation capability in the face of increased price pressures and a more challenging market environment.”

The majority of the job cuts will hit the company’s pharmaceutical division and will ultimately lead to restructuring costs of approximately 2.7 billion. In addition, the sales and marketing workforce will be slashed by a total of 2650 positions, whilst several manufacturing sites in the US and Germany will be reorganised.  

The development of preclinical research programmes will also be discontinued including that of cancer. However, the company will remain in its current therapeutic areas.

 

Are you looking for a new role in the pharmaceutical industry? Click here to search our current pharmaceutical job opportunities online now.

CK Science and CK Clinical…The Perfect Merger

Tuesday, November 2nd, 2010

CK Science and CK Clinical…The Perfect MergerWe are proud to announce that as of 1st November 2010, the two specialist recruitment consultancies, CK Science and CK Clinical will be merging and will now be known as the CK Group.

We hope you will agree that this is great news for both clients and candidates alike. As the newly formed CK Group, we aim to deliver a world class recruitment service in a socially responsible and fun way. At the core of this will be our main company values of honesty, integrity and transparency.

Here at CK, we are extremely proud to have such a rich pool of internal talent that will continue to provide you with an even more polished specialist recruitment service. In fact, one of the key reasons for the merger was to make the best use of the skills of our senior management team and to offer further training to staff. As a result, we will be continuously building on our existing strengths whilst helping to develop areas in which we as a company can improve, thus ultimately provide you with the best recruitment service possible.

Speaking of the merger of CK Clinical and CK Science, newly appointed Managing Director, Jonathan Hart-Smith stated,

“The combination of CK Science and CK Clinical as the CK Associates Group is extremely good news for our customers and the candidates we help.

“This merger creates a powerful leader in the niche recruitment industry sector, with greatly expanded areas of recruitment and a wider client and candidate base.  This means clients only have to come to one place and candidates have twice as many job opportunities available to them from one company.

“I am genuinely excited when I say that this is a great opportunity for our clients both old and new to receive a consistent quality service from the one company and the CK brand.”

Please note, that as a result of the merger, CK Science and CK Clinical will retain these trading names and the group will be known as the CK Group. The corporate entity will retain the CK Associates Ltd name.

About CK Science

CK Science was founded in 1991 by Ashley Kirk and Liam O’Connell and specialises in the recruitment of permanent and contract scientific and engineering staff for the chemical, environmental, pharmaceutical and biotechnology fields.

About CK Clinical

CK Clinical was founded in 2005 by Liam O’Connell, Ashley Kirk and Jonathan-Hartsmith. CK Clinical was founded to recruit any clinical discipline from Phase I to Phase IV and post marketed trials. The company has quickly grown to be one of the leading suppliers of clinical staff within the pharmaceutical sector.

Want to find out more? Contact Jonathan Hart-Smith, Managing Director, on 01438 743 047 or email jhartsmith@ckclinical.co.uk.

Pharmaceutical Jobs at Risk in Nottingham

Wednesday, August 11th, 2010

joblossesAs reported by the BBC News, the pharmaceutical company Vectura, has announced plans to close its site in Nottingham in a bid to cut costs. The plan could put many pharmaceutical jobs at risk.

Vectura has stated that the closure of their Ruddington Laboratories, which employ approximately 100 people could lead to a cost saving of £6 million in the next financial year.

Dr Chris Blackwell, Chief Executive of Vectura, said: “In a more cautious environment both in the sector and the economy, we believe it prudent to reduce the risk profile of Vectura while preserving the upside.

“We are accelerating our timelines to profitability and sustainable cash generation by refocusing and restructuring our R&D operations.

“This means reducing our cost base and focusing on nearer-term projects.

“The steps taken will help secure the best long-term future for Vectura.”

Vectura specialises in manufacturing inhaled medicines for the treatment of respiratory diseases. They have sites based in Witlshire and Cambridge.

Looking for a job in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.

Sanofi Aventis Proposes Takeover of Genzyme

Monday, July 26th, 2010

iStock_000006963239Medium[1]As reported by the Financial Times, the French pharmaceutical company, Sanofi Aventis, has made a preliminary takeover approach to the US biotech group, Genzyme.

It has been reported however that the approach does not constitute a formal proposal and the two companies are not currently in talks. However, Sanofi’s CEO Chris Viehbacher is reportedly considering using the company’s cash to partake in acquisitions in a bid to secure revenues as the patents on their existing drugs are set to expire.

The majority of Genzyme’s focus lies with orphan drugs – those which are used to treat rare conditions which affect a very small percentage of the population. These drugs there for come with high price tags – an attractive prospect for Sanofi.

Are you looking for a job in the pharmaceutical or biotechnology industry? Click here to search our current pharmaceutical and biotechnology jobs.

FDA to Decide the Future of GSK Drug Avandia

Monday, July 12th, 2010

According to the Wall Street Journal, the Food and Drug Administration will convene on Tuesday to discuss the future of the diabetes drug Avandia.

The battle could spark a change in the way the FDA responds to drug safety concerns and the pharmaceutical industry is concerned it may lead to a delay in drug approvals.

Studies have shown that Avandia, which is made by GlaxoSmithKline (GSK), has been linked to increased risk of heart attack.

The FDA’s own scientists have concerns about the FDA’s drug division – some believe scientists believe the agency demand too much evidence of a drugs dangers before approving it.

Read more on the Wall Street Journal website.

CK Team Building Day – Coghlans Cookery School

Friday, July 2nd, 2010

The CK Team donned their aprons earlier this month for the annual team building day.

A great day was had by all at Coghlans Cookery School in Chesterfield – where we cooked a gourmet 3 course lunch and canapés!

Lunch menu:

-          Spinach and ricotta ravioli with pesto

-          Chicken stuffed with wild mushrooms and sun dried tomatoes wrapped in parma ham

-          Focaccia bread

-          Tiramisu

-          Panna cotta

Canapes:

-          Chicken with peppers, garlic and olive oil

-          Confit of duck with mango chutney

-          Melon with mango salsa

Team spirit was high with each team dressing in their chosen team costumes – we had everything from chefs hats to bandanas and moustaches.

4744787015_5ccf4dc620    4744799773_01071d25e9    4745429644_efd6d6b33a    4745468784_c50a5cd471    4745434644_03681b5017    4745426938_c9864d1834

Quintiles to Invest $2m in Prana Biotechnology

Tuesday, June 29th, 2010

The biopharmaceutical services provider, Quintiles have announced that it will be investing up to $2m in the Australia-based Prana Biotechnology.

Quintiles has been involved with Prana’s work since the company was established in 1997. However, recently Quintiles has subscribed to Prana’s newly subscribed shares in a bid to help support a planned definitive Phase II study with PBT2 (Prana’s lead compound for Alzheimer’s disease).

Speaking of the investment, a spokesperson from Prana stated the company was “delighted to have secured an organisation of the calibre and influence of Quintiles as a significant shareholder and supporter of Prada’s therapeutic goals”.

Are you looking for a job in science? Click here to search our current science jobs now.

CK Science to Attend GSK Outplacement Event

Monday, June 14th, 2010

CK Science, the leading specialist scientific recruitment consultancy, will be attending the GSK Outplacement Event taking place on Wednesday 16th June 2010.

If you are planning to attend and would like some helpful advice to help you find a new job and would like to hear about our current pharmaceutical job vacancies which may be of interest, our specialist consultants Jim Gleeson and Julie Marshall will be happy to help you on the day.

To schedule a meeting on the day by contacting us on 01438 743 047 or email info@ckclinical.co.uk.

CK Science - Scientific Recruitment, Science Jobs, UKTwitter- CK Science, Scientific Recruitment, Science Jobs, UKLinkedin - CK Clinical, Pharmaceutical Recruitment, Pharmaceutical JobsFacebook - CK Science, Scientific Recruitment, Science Jobs, UKYoutube - CK Science, Scientific Recruitment, Science Jobs, UK

Search for a job

Advanced search

20 years Download the CK Science iPhone App

Subscribe to our newsletter

Preview
Powered by FeedBlitz